02/19/2026
We'd like to introduce you to Dr. Sindhu Johnson, who will be speaking at the upcoming National Scleroderma Conference. Dr. Johnson is a Rheumatologist and Professor of Medicine at the University of Toronto, and Director of the Toronto Scleroderma Program.
She graduated from medical school at Memorial University of Newfoundland, followed by residencies in Internal Medicine and Rheumatology at the University of Toronto. She completed a PhD in Clinical Epidemiology through the Institute of Health Policy, Management and Evaluation. Her research focuses on observational studies and clinical trials to better understand scleroderma, how it impacts peoples’ lives, develop better treatments and discover a cure. She was a scientist for studies that led to the first two US Food and Drug Administration approved treatments for scleroderma (nintedinib, tocilizumab). She is the Principal Investigator for the American College of Rheumatology and American College of Chest Physicians Guidelines for the screening, monitoring and treatment of interstitial lung disease in people with scleroderma.
